Evidence map›Paper›PMID 38817228›Full record

ArticleWorld journal of clinical cases2024

Recent trends in bone metastasis treatments: A historical comparison using the new Katagiri score system.

Kenji Matsuda, Kazuhiro Shimazu, Hanae Shinozaki, Koji Fukuda, Taichi Yoshida, Daiki Taguchi, Kyoko Nomura, Hiroyuki Shibata

Abstract read
In one paragraph

Article in World journal of clinical cases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kenji MatsudaDepartment of Clinical Oncology, Akita University Graduate School of Medicine, Akita 010-8543, Japan.
Kazuhiro ShimazuDepartment of Clinical Oncology, Akita University Graduate School of Medicine, Akita 010-8543, Japan.
Hanae ShinozakiDepartment of Clinical Oncology, Akita University Graduate School of Medicine, Akita 010-8543, Japan.
Koji FukudaDepartment of Clinical Oncology, Akita University Graduate School of Medicine, Akita 010-8543, Japan.
Taichi YoshidaDepartment of Clinical Oncology, Akita University Graduate School of Medicine, Akita 010-8543, Japan.
Daiki TaguchiDepartment of Clinical Oncology, Akita University Graduate School of Medicine, Akita 010-8543, Japan.
Kyoko NomuraDepartment of Environmental Health Science and Public Health, Akita University Graduate School of Medicine, Akita 010-8543, Japan.
Hiroyuki ShibataDepartment of Clinical Oncology, Akita University Graduate School of Medicine, Akita 010-8543, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBone metastasis has various negative impacts. Activities of daily living (ADL) and quality of life (QOL) can be significantly decreased, survival may be impacted, and medical expenses may increase. It is estimated that at least 5% cancer patients might be suffering from bone metastases. In 2016, we published the Comprehensive Guidelines for the Diagnosis and Treatment of Bone Metastasis. Since then, the therapeutic outcomes for patients have gradually improved. As life expectancy is a major determinant of surgical intervention, the strategy should be modified if the prolongation of survival is to be achieved.

aimTo monitor how bone metastasis treatment has changed before and after launch of our guidelines for bone metastasis.

methodsFor advanced cancer patients with bone metastasis who visited the Department of Clinical Oncology at Akita University hospital between 2012 and 2023, parameters including the site and number of bone metastases, laboratory data, and survival time, were extracted from electronic medical records and the Katagiri score was calculated. The association with survival was determined for each factor.

resultsData from 136 patients were obtained. The 1-year survival rate for the poor prognosis group with a higher Katagiri score was 20.0% in this study, which was 6% and an apparent improvement from 2014 when the scoring system was developed. Other factors significantly affecting survival included five or more bone metastases than less (

conclusionVarious therapeutic interventions including surgical approach for bone metastasis, which is a disorder of locomotor organs, are increasingly required. Guidelines and scoring system for prognosis need to be revised promptly.

Indexed as

Bone metastasisImmune check point inhibitorsNew Katagiri scoring systemPrognosisSurvival

Identifiers

PMID38817228
PMCPMC11135455

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.